Investment Thesis
NextCure demonstrates exceptional 252.6% YoY revenue growth indicating strong commercialization momentum; however, severe operating losses (-45.2% margin), negative free cash flow of -13.8M, and limited cash runway (~13 months at current burn rate) present material solvency risk. The clean balance sheet and zero debt provide some cushion, but the company must achieve profitability or secure additional funding before cash depletion.
Strengths
- Exceptional revenue growth of 252.6% YoY indicating strong market traction and commercialization progress
- Fortress balance sheet with zero long-term debt and 15.2M cash, reducing financial leverage risk
- Excellent liquidity position with 4.61x current and quick ratios, ensuring near-term payment obligations
- Improving diluted EPS trend (+17.7% YoY) suggests operational efficiency gains despite unprofitability
Risks
- Severe cash burn with negative operating cash flow of -13.4M and free cash flow of -13.8M, indicating only ~13 months of runway at current rates
- Persistent unprofitability with -43.8% net margin and -45.2% operating margin despite revenue growth, signaling inability to scale efficiently
- Unclear path to profitability with no evidence of margin improvement trajectory as company scales
- Pharmaceutical sector execution risk: clinical development timelines, regulatory approval uncertainty, and competitive pressures remain unquantified
Key Metrics to Watch
- Quarterly operating cash flow trend and path to positive FCF
- Gross margin expansion as product mix matures and volumes increase
- Cash burn rate and updated runway estimates per quarterly filings
- Revenue growth sustainability and product-level profitability metrics
- Progress on clinical pipeline and regulatory milestones
Financial Metrics
Revenue
22.4M
Net Income
-9.8M
EPS (Diluted)
$-1.87
Free Cash Flow
-13.8M
Total Assets
38.0M
Cash
15.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-45.2%
Net Margin
-43.8%
ROE
-36.7%
ROA
-25.8%
FCF Margin
-61.8%
Balance Sheet & Liquidity
Current Ratio
4.61x
Quick Ratio
4.61x
Debt/Equity
0.00x
Debt/Assets
29.7%
Interest Coverage
-55.22x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:12:34.027139 |
Data as of: 2026-03-31 |
Powered by Claude AI